A 23 year old man presented with a tumour mass in the lung. Subsequent investigation showed ectopic secretion of adrenocorticotrophic hormone (ACTH) and growth hormone releasing hormone (GHRH) from an adenoid cystic carcinoma. The patient progressed to show the clinical effects of long term exposure to high blood levels of both growth hormone and cortisol. The case was complicated by pituitary infarction. The very high blood levels of ACTH, growth hormone (GH) and GHRH proved resistant to treatment with the somatostatin analogue, SMS 201-995, and a possible side effect of the drug is reported. To our knowledge this is the first reported case of ectopic hormone secretion by an adenoid cystic carcinoma.
Introduction
Acromegaly due to ectopic production of growth hormone releasing hormone (GHRH) has been described in association with a variety of tumours including carcinoid and pancreatic islet cell tumours.1 2'3'4 More than one ectopic hormone may be present in the tumour; in one reported case of metastatic carcinoid presenting clinically with acromegaly, gigantism and Cushing's syndrome,1 for example, both growth hormone (GH) and GHRH were identified in the tumour. However, the presence of immunoreactive hormone in tumour tissue is not necessarily synonymous with ectopic hormone secretion; in one case of metastatic carcinoid, growth hormone was present in the tumour but no arteriovenous gradient was demonstrated across it. 5We report a case of ectopic secretion of GHRH and adrenocorticotrophic hormone (ACTH) from an adenoid cystic carcinoma with failure to respond to the somatostatin analogue SMS-201-995 (Sandoz). The case was further complicated by pituitary infarction. To our knowledge this is the first reported case of ectopic secretion by adenoid cystic carcinoma. Some initial biochemical investigations are shown in Table I . Plasma cortisol levels which were high with no diurnal variation and no response to either low dose (2mg overnight) or high dose (2mg four times daily for 4 days) dexamethasone. Standard luteinising hormone releasing hormone (LHRH) and thyrotrophin releasing hormone (TRH) tests were performed; the results are shown in Table II . Basal testosterone was low and there was an exaggerated luteinising hormone (LH) response to LHRH. Although prolactin levels were markedly raised they subsequently fluctuated between 320 and 460m U/l during a 6 hour saline infusion. Plasma GH levels -which were lower than on previous Pituitary function tests were performed on 1 October 1984. Basal TSH, LH, follicle stimulating hormone (FSH) and growth hormone were below the level of detection and showed no response to TRH and LHRH. Both total thyroxine (34nmol/l) and 'free' thyroxine (4.0 pmol/l) were low but plasma cortisol, ACTH and GHRH levels remained high. Over the 6 months period following the presumed pituitary infarction, plasma insulin-like growth factor I (IGF-1) levels fell from 5.6 to 0.2 IU/I and prolactin levels fell to less than 50 mU/l.
Pre-infarction plasma levels of gastrin, vasoactive intestinal polypeptide (VIP), glucagon, calcitonin, somatostatin and bombesin were normal at all times. Corticotrophin releasing factor (CRF) was undetectable in plasma both before and after pituitary infarction.
Immunoperoxidase staining of the tumour biopsy showed both ACTH and GHRH. No immunochemical CRF, GH or 5 hydroxytryptamine (5HT) was demonstrated. After further courses of chemotherapy and radiotherapy the patient gradually deteriorated and died some 9 months after the events described. A post-mortem examination was not obtained.
Discussion
This patient demonstrates ectopic production of both GHRH and ACTH by an adenoid cystic carcinoma. These tumours arise in the bronchus, trachea, breast or salivary gland and have a characteristic histological appearance.6 They have not previously been known to be associated with ectopic GHRH or ACTH production.
Although arterio-venous differences across the tumour were not measured the evidence for ectopic production is good: (i) the failure of plasma ACTH and cortisol levels to respond to high dose dexamethasone;7 (ii) the persistence, following pituitary infarction of high plasma cortisol and ACTH levels; and (iii) the immunocytochemical demonstration of ACTH in the tumour.
Similarly, the presence of grossly elevated levels of GHRH in peripheral venous blood, with a fall in the high levels of growth hormone and IGF-1 but not GHRH, following pituitary infarction, together with the large amounts of GHRH demonstrated immunocytochemically in the tumour tissue, point to ectopic secretion of GHRH.
The somatostatin analogue, SMS 201-995, failed to suppress the elevated levels of GH, insulin, glucose, GHRH or ACTH which contrasts with the findings in regular acromegaly where somatostatin and its analogues consistently lower basal GH8-12 and insulin levels1 3 and block the response to exogenous GHRH. [8] [9] [10] [11] [12] The acute onset diarrhoea may have been a side effect of the drug but the case was complicated by pituitary infarction. Pancreatic steatorrhoea has been reported17 in patients receiving long term therapy with a higher dose of SMS 201-995.
The findings of a rise in plasma GH in response to TRH is in accord with the findings of Schulte14 in another patient with a GHRH-producing tumour. Our patient also had insulin-dependent diabetes mellitus -itself a cause of GH responsiveness to TRH. 15 The reason for the GH response to TRH is not clear; it has been suggested that somatotroph hyperplasia secondary to hyperstimulation by GHRH permits TRH to become a secretagogue for GH16 but this must still be considered conjectural.
